Chronic treatment with caffeine and its withdrawal modify the antidepressant-like activity of selective serotonin reuptake inhibitors in the forced swim and tail suspension tests in mice. Effects on Comt , Slc6a15 and Adora1 gene expression

Szopa, Aleksandra; Doboszewska, Urszula; Herbet, Mariola; Wośko, Sylwia; Wyska, Elżbieta; Świąder, Katarzyna; Serefko, Anna; Korga, Agnieszka; Właź, Aleksandra; Wróbel, Andrzej; Ostrowska, Marta; Terlecka, Joanna; Kanadys, Adam; Poleszak, Ewa; Dudka, Jarosław; Właź, Piotr

doi:10.1016/j.taap.2017.10.020

Cited by 11 publications

(7 citation statements)

References 64 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It has been previously demonstrated that non-selective AR antagonist, caffeine, at a non-effective dose (5 mg/kg) potentiated the activity of antidepressants belonging to different classes (i.e., fluoxetine, paroxetine, escitalopram, imipramine, desipramine, reboxetine, venlafaxine, moclobemide, mianserin, milnacipran, bupropion, and agomelatine) (Kale and Addepalli 2014 ; Poleszak et al 2015 , 2016b ; Szopa et al 2016 , 2017 ). The antidepressant-like effect of the analyzed drug-drug combinations (DMPX-imipramine, DMPX-escitalopram, and DMPX-reboxetine) observed in our study is probably the result of the sum of their action on the monoaminergic transmission.…”

Section: Discussionmentioning

confidence: 99%

Antidepressant-Like Activity of Typical Antidepressant Drugs in the Forced Swim Test and Tail Suspension Test in Mice Is Augmented by DMPX, an Adenosine A2A Receptor Antagonist

et al. 2018

Self Cite

View full text Add to dashboard Cite

Unsatisfactory therapeutic effects of currently used antidepressants force to search for new pharmacological treatment strategies. Recent research points to the relationship between depressive disorders and the adenosinergic system. Therefore, the main goal of our studies was to evaluate the effects of DMPX (3 mg/kg, i.p.), which possesses selectivity for adenosine A2A receptors versus A1 receptors, on the activity of imipramine (15 mg/kg, i.p.), escitalopram (2.5 mg/kg, i.p.), and reboxetine (2 mg/kg, i.p.) given in subtherapeutic doses. The studies carried out using the forced swim and tail suspension tests in mice showed that DMPX at a dose of 6 and 12 mg/kg exerts antidepressant-like effect and does not affect the locomotor activity. Co-administration of DMPX at a dose of 3 mg/kg with the studied antidepressant drugs caused the reduction of immobility time in both behavioral tests. The observed effect was not associated with an increase in the locomotor activity. To evaluate whether the observed effects were due to a pharmacokinetic/pharmacodynamic interaction, the levels of the antidepressants in blood and brain were measured using high-performance liquid chromatography. It can be assumed that the interaction between DMPX and imipramine was exclusively pharmacodynamic in nature, whereas an increased antidepressant activity of escitalopram and reboxetine was at least partly related to its pharmacokinetic interaction with DMPX.

show abstract

Section: Discussionmentioning

confidence: 99%

Antidepressant-Like Activity of Typical Antidepressant Drugs in the Forced Swim Test and Tail Suspension Test in Mice Is Augmented by DMPX, an Adenosine A2A Receptor Antagonist

et al. 2018

Self Cite

View full text Add to dashboard Cite

show abstract

“…Our data point to the involvement of A 1 receptors in the mechanism of action of mianserin as well as in the mechanism underlying beneficial effects of caffeine on the antidepressant treatment. We have previously demonstrated that decreased Adora1 expression in the Cx was parallel to the antidepressant-like effect of joint administration of caffeine and escitalopram, but not fluoxetine, in mice chronically treated with caffeine (Szopa et al 2017). …”

Section: Discussionmentioning

confidence: 94%

“…Moreover, the antidepressant-like effect observed after joint administration of agomelatine or mianserin and caffeine on day 15 in mice chronically treated with caffeine was associated with a decreased expression of Slc6a15 at mRNA level in the Cx. We have previously demonstrated that co-administration of single doses of SSRIs, fluoxetine or escitalopram, and caffeine in mice chronically (for 2 weeks) treated with caffeine led to a decreased Slc6a15 level in the Cx, which was associated with an antidepressant-like effect in the FST and TST (Szopa et al 2017 ). Another group has shown that chronic (14-day) treatment with low (3 mg/kg) or high (10 mg/kg) dose of fluoxetine caused an upregulation of Slc6a15 at mRNA level in the hippocampus (Hagglund et al 2013 ), which points to the role of this gene in the mechanism of action of this drug.…”

Section: Discussionmentioning

confidence: 98%

Withdrawal of caffeine after its chronic administration modifies the antidepressant-like activity of atypical antidepressants in mice. Changes in cortical expression of Comt, Slc6a15 and Adora1 genes

et al. 2018

Self Cite

View full text Add to dashboard Cite

RationaleDepressed patients often present increased consumption of caffeine.ObjectivesWe aimed to investigate the effects of chronic treatment with caffeine (5 mg/kg, twice daily for 14 days) on the activity of single, ineffective doses of agomelatine (20 mg/kg) or mianserin (10 mg/kg) given on day 15 alone or simultaneously with caffeine.MethodsWe used the forced swim test (FST), tail suspension test (TST), and locomotor activity test in mice and quantitative real-time PCR analysis of the selected genes in the cerebral cortex (Cx).ResultsThere were no changes in the immobility time between mice that received saline and caffeine for 14 days. Administration of agomelatine or mianserin on day 15 did not produce an antidepressant-like effect, but such effect was observed after administration of agomelatine or mianserin simultaneously with caffeine on day 15, in both mice that received saline and caffeine for 14 days. In mice treated with caffeine for 14 days, joint administration of agomelatine or mianserin and caffeine on day 15 decreased solute carrier family 6, member 15 (Slc6a15), messenger RNA (mRNA) level in the Cx, compared to the group which received only the respective antidepressant on this day. Moreover, in mice treated with caffeine for 14 days, joint administration of mianserin and caffeine on day 15 decreased adenosine A1 receptor (Adora1) and catechol-O-methyltransferase (Comt) mRNA level in the Cx, compared to the group which received mianserin without caffeine on this day.ConclusionsWithdrawal of caffeine after its chronic intake can modify the activity of antidepressants. Adora1, Slc6a15, and Comt may be involved in the antidepressant-like effect observed after joint administration of caffeine and mianserin or agomelatine, following chronic treatment with caffeine.

show abstract

“…Mice were considered immobile only when they hung passively and completely motionless. Immobility time was manually recorded during a 6 min period by an experienced observer who was blind to the animal condition, as previously reported (Can et al, 2017; Pałucha-Poniewiera et al, 2017; Podkowa et al, 2018; Szopa et al, 2017).…”

Section: Methodsmentioning

confidence: 99%

Silymarin and silymarin nanoparticles guard against chronic unpredictable mild stress induced depressive-like behavior in mice: involvement of neurogenesis and NLRP3 inflammasome

et al. 2019

View full text Add to dashboard Cite

Background: The neuropathology of depression is quite complex. Thus, treatment failures are frequent with current antidepressants, raising the need for more effective ones. Aims: This study aimed to investigate the influence of silymarin on depressive-like behavior induced by chronic unpredictable mild stress (CUMS) and explore the underlying mechanisms. Methods: Silymarin was formulated as nanostructured lipid carriers (a lipid-based type of nanoparticle with the advantages of physical stability, good release profile, and targeted delivery). Mice were subjected to CUMS paradigm during 14 days. During this period, mice received silymarin (200 mg/kg, p.o.) per se or in its nanoparticle form or fluoxetine (10 mg/kg, p.o.). On the 15th day behavioral and biochemical parameters were analyzed. Results: Oral administration of silymarin (200 mg/kg), particularly in its nanoparticulate form, exerted an antidepressant-like effect, comparable with fluoxetine in mice, as demonstrated in the behavioral despair tests. Silymarin also reversed prefrontal cortical and hippocampal CUMS-induced oxidative stress and neuroinflammation. Furthermore, silymarin augmented neurotransmitter levels, enhanced neurogenesis and inhibited nod-like receptor protein 3 inflammasome activation. Silymarin nanoparticles were superior to silymarin in certain parameters probably due to significantly higher brain silybinin (the major active component of silymarin) concentration by 12.46 fold in the group administered silymarin nanoparticles compared with the mice which were administered silymarin per se. Conclusions: The antidepressant-like effect of silymarin can be attributed to its antioxidant and anti-inflammatory effects as well as increased neurogenesis in the prefrontal cortex and hippocampus, which delineates silymarin, especially in nanoparticle form, as a promising strategy for treatment of depression.

show abstract

Chronic treatment with caffeine and its withdrawal modify the antidepressant-like activity of selective serotonin reuptake inhibitors in the forced swim and tail suspension tests in mice. Effects on Comt , Slc6a15 and Adora1 gene expression

Cited by 11 publications

References 64 publications

Antidepressant-Like Activity of Typical Antidepressant Drugs in the Forced Swim Test and Tail Suspension Test in Mice Is Augmented by DMPX, an Adenosine A2A Receptor Antagonist

Antidepressant-Like Activity of Typical Antidepressant Drugs in the Forced Swim Test and Tail Suspension Test in Mice Is Augmented by DMPX, an Adenosine A2A Receptor Antagonist

Withdrawal of caffeine after its chronic administration modifies the antidepressant-like activity of atypical antidepressants in mice. Changes in cortical expression of Comt, Slc6a15 and Adora1 genes

Silymarin and silymarin nanoparticles guard against chronic unpredictable mild stress induced depressive-like behavior in mice: involvement of neurogenesis and NLRP3 inflammasome

Contact Info

Product

Resources

About